Edgewise Therapeutics Income Statement (2020-2026) | EWTX

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
49.30M37.53M49.56M49.78M51.84M63.26M63.27M63.46M63.46M70.45M93.28M93.64M94.41M94.84M95.21M105.34M105.76M106.25M107.48M107.78M
Operating items
Research & Development (Quarter)
9.88M9.09M11.12M12.40M13.89M16.61M19.88M19.56M23.79M27.68M27.69M30.68M32.22M36.37M36.76M33.56M37.48M43.59M42.65M47.55M
Selling, General & Administrative (Quarter)
3.20M3.73M3.70M4.09M4.37M5.47M5.83M5.78M5.67M6.18M7.06M7.43M8.21M9.17M9.20M9.05M9.38M12.38M11.46M14.39M
Operating Expenses (Quarter)
13.08M12.82M14.83M16.49M18.26M22.08M25.70M25.34M29.45M33.86M34.75M38.11M40.43M45.54M45.96M42.61M46.86M55.98M54.12M61.94M
Operating Income (Quarter)
-13.08M-12.82M-14.83M-16.49M-18.26M-22.08M-25.70M-25.34M-29.45M-33.86M-34.75M-38.11M-40.43M-45.54M-45.96M-42.61M-46.86M-55.98M-54.12M-61.94M
EBIT (Quarter)
-13.08M-12.82M-14.83M-16.49M-18.26M-22.08M-25.70M-25.34M-29.45M-33.86M-34.75M-38.11M-40.43M-45.54M-45.96M-42.61M-46.86M-55.98M-54.12M-61.94M
Non-operating items
Interest & Investment Income (Quarter)
0.13M0.13M0.17M0.42M0.76M2.66M2.87M3.87M3.74M3.72M6.23M6.61M6.30M5.88M5.16M6.50M6.19M5.76M5.10M4.62M
Other Non Operating Income (Quarter)
0.13M0.13M0.17M0.42M0.76M2.66M2.87M3.87M3.74M3.72M6.23M6.61M6.30M5.88M5.16M6.50M6.19M5.76M5.10M4.62M
Non Operating Income (Quarter)
6.23M6.61M6.30M5.88M5.16M6.50M6.19M
Net income details
EBT (Quarter)
-12.95M-12.84M-17.96M-16.52M-18.20M-19.85M-29.93M-28.49M-27.01M-30.20M-34.90M-32.56M-34.13M-44.26M-40.80M-36.12M-40.67M-54.02M-49.01M-57.33M
Profit After Tax (Quarter)
-12.94M-12.67M-14.66M-16.07M-17.34M-20.26M-22.84M-21.47M-25.71M-28.69M-28.52M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.50M-49.94M-57.58M
Income from Non-Controlling Interests (Quarter)
0.01M-0.49M-1.42M-0.40M0.16M0.82M1.10M-0.30M0.12M0.52M-0.96M-0.19M2.10M-0.63M-0.02M-0.20M0.50M-0.02M-0.93M-0.25M
Income from Continuing Operations (Quarter)
-12.95M-12.84M-17.96M-16.52M-18.20M-19.85M-29.93M-28.49M-27.01M-30.20M-34.90M-32.56M-34.13M-44.26M-40.80M-36.12M-40.67M-54.02M-49.01M-57.33M
Consolidated Net Income (Quarter)
-12.95M-12.84M-17.96M-16.52M-18.20M-19.85M-29.93M-28.49M-27.01M-30.20M-34.90M-32.56M-34.13M-44.26M-40.80M-36.12M-40.67M-54.02M-49.01M-57.33M
Income towards Parent Company (Quarter)
-12.95M-12.84M-17.96M-16.52M-18.20M-19.85M-29.93M-28.49M-27.01M-30.20M-34.90M-32.56M-34.13M-44.26M-40.80M-36.12M-40.67M-54.02M-49.01M-57.33M
Net Income towards Common Stockholders (Quarter)
-12.95M-12.84M-17.96M-16.52M-18.20M-19.85M-29.93M-28.49M-27.01M-30.20M-34.90M-32.56M-34.13M-44.26M-40.80M-36.12M-40.67M-54.02M-49.01M-57.33M
Additional items
EPS (Basic) (Quarter)
-0.26-0.34-0.36-0.33-0.35-0.37-0.47-0.45-0.43-0.47-0.40-0.35-0.36-0.48-0.43-0.34-0.39-0.52-0.46-0.53
EPS (Diluted) (Quarter)
-0.26-0.34-0.36-0.33-0.35-0.37-0.47-0.45-0.43-0.47-0.40-0.35-0.36-0.48-0.43-0.34-0.39-0.52-0.46-0.53
Shares Outstanding (Quarter)
49.26M37.53M49.54M49.62M51.84M53.59M63.27M63.38M63.46M63.72M87.57M93.52M93.81M92.41M95.13M104.94M105.49M102.93M107.12M107.67M
Shares Outstanding (Diluted) (Quarter)
49.26M37.53M49.54M49.62M51.84M53.59M63.27M63.38M63.46M63.72M87.57M93.52M93.81M92.41M95.13M104.94M105.49M102.93M107.12M107.67M
EBITDA (Quarter)
-13.08M-12.82M-14.83M-16.49M-18.26M-22.08M-25.70M-25.34M-29.45M-33.86M-34.75M-38.11M-40.43M-45.54M-45.96M-42.61M-46.86M-55.98M-54.12M-61.94M
Interest Expenses (Quarter)
0.14M3.30M0.46M0.70M0.43M7.09M7.03M1.29M0.05M6.37M1.07M4.60M3.80M